Jiangsu Recbio Technology Co., Ltd. (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that positive results were achieved for its primary vaccination Phase II study in the Philippines and heterologous booster vaccination Phase II study in United Arab Emirates (“UAE”) in respect of its recombinant COVID-19 vaccine ReCOV. The studies showed that ReCOV had demonstrated good safety profile and excellent immune response and was able to provide definite cross-protection from the Omicron variants (including the epidemic strain BA4/5), outperforming the international mainstream vaccines reported to date.